Get the Stockscreener App
1.79
0.56%
-0.01
After Hours:
1.82
0.03
+1.68%
Inhibikase Therapeutics Inc stock is traded at $1.79, with a volume of 692.79K.
It is down -0.56% in the last 24 hours and down -4.79% over the past month.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
See More
Previous Close:
$1.80
Open:
$1.78
24h Volume:
692.79K
Relative Volume:
0.40
Market Cap:
$236.34M
Revenue:
$79,600
Net Income/Loss:
$-48.26M
P/E Ratio:
-3.6367
EPS:
-0.4922
Net Cash Flow:
$-28.24M
1W Performance:
+13.29%
1M Performance:
-4.79%
6M Performance:
+10.49%
1Y Performance:
-2.72%
1-Day Range:
$1.745
$1.83
1-Week Range:
$1.59
$1.83
52-Week Range:
$1.33
$2.365
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
(302) 295-3800
Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.79 | 237.66M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Initiated | Ladenburg Thalmann | Buy |
| Jan-21-26 | Initiated | BofA Securities | Buy |
| Dec-26-25 | Initiated | H.C. Wainwright | Buy |
| Dec-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Inhibikase grants stock options to new employees under inducement plan - MSN
Inhibikase Grants Stock Options to New Employees Under Inducement Plan - MyChesCo
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Inhibikase Therapeutics Announces Inducement Grants - National Today
Inhibikase Therapeutics Grants Inducement Shares to New Hires - National Today
Five new Inhibikase hires get stock options priced at $1.68 - Stock Titan
IKT Technical Analysis & Stock Price Forecast - Intellectia AI
HC Wainwright Has Optimistic Outlook of IKT Q1 Earnings - Defense World
Nocion Therapeutics Appoints Mark Iwicki To Board - citybiz
HC Wainwright Issues Positive Estimate for IKT Earnings - MarketBeat
Death Cross: What is the next catalyst for Inhibikase Therapeutics Inc2026 Update & Safe Capital Investment Plans - baoquankhu1.vn
Inhibikase Therapeutics, Inc. 2025 Annual Report: Pipeline, Intellectual Property, and PAH Drug Development Overview - Minichart
Inhibikase Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Inhibikase Therapeutics 10-K: Operating loss $51.97M, Net loss $48.26M, Interest income $3.72M - TradingView
Inhibikase (NASDAQ: IKT) pivots to PAH drug IKT-001 with Phase 3 trial and $115M raise - Stock Titan
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Inhibikase (NASDAQ: IKT) boosts cash as 2025 loss grows and PAH Phase 3 advances - Stock Titan
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity - The Manila Times
Press Release: Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity - Moomoo
Surprises Report: What is the Moat Score of Inhibikase Therapeutics IncQuarterly Performance Summary & Entry and Exit Point Strategies - baoquankhu1.vn
Inhibikase Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
IKT Stock Price, Quote & Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February - MarketBeat
Aug Ideas: Does Inhibikase Therapeutics Inc stock benefit from AI growth2026 Retail & Low Drawdown Trading Techniques - baoquankhu1.vn
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Analysts - MarketBeat
Reviewing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
IKT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Inhibikase Therapeutics (NASDAQ:IKT) Stock Rating Upgraded by LADENBURG THALM/SH SH - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH - MarketBeat
Inhibikase Therapeutics (IKT) Gains New Coverage with 'Buy' Rati - GuruFocus
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Update - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Coverage Initiated at LADENBURG THALM/SH SH - MarketBeat
Ladenburg Thalmann Initiates Inhibikase Therapeutics at Buy - marketscreener.com
Athira Pharma (NASDAQ:LONA) versus Inhibikase Therapeutics (NASDAQ:IKT) Head-To-Head Analysis - Defense World
FY2025 Earnings Forecast for IKT Issued By Lifesci Capital - Defense World
A Look At Inhibikase Therapeutics (IKT) Valuation After New FDA Designations And Phase 2a Trial Progress - simplywall.st
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4%Still a Buy? - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4% – Still a Buy? - Defense World
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Lifesci Capital to "Strong-Buy" Rating - MarketBeat
Analyzing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
IKT Stock Surge: What’s Driving the 13% Jump Today? - Creative Learning Guild
Inhibikase (IKT) R&D president forfeits 338,282 milestone-based shares - Stock Titan
Inhibikase (IKT) director Amit Munshi forfeits 19,089 milestone-based shares - Stock Titan
IKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IKT Stock Bounces Amid Steady Growth Potential - StocksToTrade
Inhibikase Therapeutics: A Surge in Market Interest on Recent Developments - timothysykes.com
IKT Surges Amid Strategic Developments and Market Shifts - StocksToTrade
Inhibikase Therapeutics Stock Faces Challenges Amid Financial Uncertainty - timothysykes.com
Certain Warrants of Inhibikase Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-FEB-2026. - marketscreener.com
ADAR1 group discloses 9.9% Inhibikase (IKT) ownership via shares and warrants - Stock Titan
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):